Huaijin Gao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Huaijin Gao has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
Baorong Gu
1 shared publicationBowen Qiu
1 shared publicationDan Wu
1 shared publication- Dan Wu
Department of Biomedical Engineering, College of Biomedical Engineering & Instrument Science, Zhejiang University
1 shared publication Manli Huang
1 shared publicationRui Qian
1 shared publication
Latest Publications
- Open Access
Resolving Heterogeneity in Major Depression: Overcoupling and Undercoupling Subtypes Exhibit Differential Treatment Response and Molecular Pathways
Major depressive disorder (MDD) exhibits significant heterogeneity whose neurobiological mechanisms remain elusive. Alterations in morphological-functional coupling (MFC) have been observed in MDD. This study aims to investigate MDD subtypes based on MFC alterations and their associations with clinical symptoms and molecular basis. We identified two clinically distinct MDD subtypes in multi-center neuroimaging data (Discovery: 828 MDD/776 healthy controls; Validation: 236 MDD/86 healthy controls) by using a semi-supervised machine learning approach based on MFC changes, which were validated and robustly repeated in the validation dataset. Differences among subtypes were then examined in relation to clinical assessments, gene expression patterns, neurotransmitter and cell density, and treatment response. Subtype I (overcoupling) showed elevated MFC in high-order association cortices, linking to synaptic transmission activity and severe symptoms. Subtype II (undercoupling) demonstrated reduced MFC in primary cortices, associated with cell cycle regulation and treatment resistance. Both subtypes shared molecular signatures (cell types: astrocytes and oligodendrocytes; neurotransmitter systems: serotonergic and GABAergic receptors). Crucially, longitudinal data (33 MDD undergoing Escitalopram monotherapy) revealed that undercoupling subtype exhibited better response, implying a potential mechanism of the drug via increasing the MFC. Our work deciphers MFC-driven MDD phenotypes with distinct molecular profiles and differential treatment outcomes, suggesting potential pathways for personalized diagnosis and treatment strategies in MDD, advancing precision psychiatry.
Open AccessResolving Heterogeneity in Major Depression: Overcoupling and Undercoupling Subtypes Exhibit Differential Treatment Response and Molecular Pathways
Major depressive disorder (MDD) exhibits significant heterogeneity whose neurobiological mechanisms remain elusive. Alterations in morphological-functional coupling (MFC) have been observed in MDD. This study aims to investigate MDD subtypes based on MFC alterations and their associations with clinical symptoms and molecular basis. We identified two clinically distinct MDD subtypes in multi-center neuroimaging data (Discovery: 828 MDD/776 healthy controls; Validation: 236 MDD/86 healthy controls) by using a semi-supervised machine learning approach based on MFC changes, which were validated and robustly repeated in the validation dataset. Differences among subtypes were then examined in relation to clinical assessments, gene expression patterns, neurotransmitter and cell density, and treatment response. Subtype I (overcoupling) showed elevated MFC in high-order association cortices, linking to synaptic transmission activity and severe symptoms. Subtype II (undercoupling) demonstrated reduced MFC in primary cortices, associated with cell cycle regulation and treatment resistance. Both subtypes shared molecular signatures (cell types: astrocytes and oligodendrocytes; neurotransmitter systems: serotonergic and GABAergic receptors). Crucially, longitudinal data (33 MDD undergoing Escitalopram monotherapy) revealed that undercoupling subtype exhibited better response, implying a potential mechanism of the drug via increasing the MFC. Our work deciphers MFC-driven MDD phenotypes with distinct molecular profiles and differential treatment outcomes, suggesting potential pathways for personalized diagnosis and treatment strategies in MDD, advancing precision psychiatry.
- Open Access
- 1 January 2025
- Published by Wiley in Depression and Anxiety
- Vol. 2025 (1) , 3864020
Altered Global Signal Topography in Major Depressive Disorder With and Without Anxiety
Background: Major depressive disorder (MDD) is a psychiatric disorder characterized by alterations in global signal (GS) topography across various neural networks and brain regions, including the default mode network and sensorimotor‐related areas. While previous research has demonstrated the potential of global brain activity measures to differentiate MDD from healthy controls (HCs), specific changes in GS distribution among MDD patients with and without anxiety remain poorly understood. This study aims to investigate anxiety‐related alterations in GS topography in MDD and their associations with clinical symptoms. Methods: Resting‐state functional magnetic resonance imaging (fMRI) and T1‐weighted imaging data were collected from 334 MDD patients with anxiety, 145 MDD patients without anxiety, and 307 HCs as part of the REST‐meta‐MDD consortium. We computed GS topography using GS correlation (GSCORR) and assessed structural–functional interaction (SFI) by examining the relationship between gray matter volume and GS for each subject. Results: Our analysis revealed no significant differences in GS topography among the three groups at either the whole‐brain or network levels. However, decreased GSCORR was observed in the right precentral gyrus, insula, and posterior parieto‐occipital cortex in anxious MDD patients compared to HC. SFI analyses indicated anxiety‐related alterations in the sensorimotor network, precuneus, putamen, and middle temporal gyrus. Moreover, GSCORR in the inferior parietal lobe and cerebellum exhibited specific correlation trends with anxiety and depression symptoms, respectively. Conclusions: These findings underscore an abnormal topographic shift in global brain activity in MDD patients with anxiety, offering a new insight into understanding brain dysfunction associated with this disorder.
- 1 January 2025
- Published by Wiley in Depression and Anxiety
- Vol. 2025 (1) , 3864020
Open AccessAltered Global Signal Topography in Major Depressive Disorder With and Without Anxiety
Background: Major depressive disorder (MDD) is a psychiatric disorder characterized by alterations in global signal (GS) topography across various neural networks and brain regions, including the default mode network and sensorimotor‐related areas. While previous research has demonstrated the potential of global brain activity measures to differentiate MDD from healthy controls (HCs), specific changes in GS distribution among MDD patients with and without anxiety remain poorly understood. This study aims to investigate anxiety‐related alterations in GS topography in MDD and their associations with clinical symptoms. Methods: Resting‐state functional magnetic resonance imaging (fMRI) and T1‐weighted imaging data were collected from 334 MDD patients with anxiety, 145 MDD patients without anxiety, and 307 HCs as part of the REST‐meta‐MDD consortium. We computed GS topography using GS correlation (GSCORR) and assessed structural–functional interaction (SFI) by examining the relationship between gray matter volume and GS for each subject. Results: Our analysis revealed no significant differences in GS topography among the three groups at either the whole‐brain or network levels. However, decreased GSCORR was observed in the right precentral gyrus, insula, and posterior parieto‐occipital cortex in anxious MDD patients compared to HC. SFI analyses indicated anxiety‐related alterations in the sensorimotor network, precuneus, putamen, and middle temporal gyrus. Moreover, GSCORR in the inferior parietal lobe and cerebellum exhibited specific correlation trends with anxiety and depression symptoms, respectively. Conclusions: These findings underscore an abnormal topographic shift in global brain activity in MDD patients with anxiety, offering a new insight into understanding brain dysfunction associated with this disorder.